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Letters to the Editor
Proper Reporting of Statistical 
Parameters in Clinical Trials 
Published in Indian Medical 
Journals. Is Inclusion of 
Statistician Play any Significant 
Role?
Sir,
It is observed that the clinical trials published in various 
medical journals are poor in reporting of various 
methodological aspects, including sample size calculation 
and power.[1] It is difficult to generalize the results of 
clinical trials having poor reporting of statistics to the 
normal patient population and conducting these clinical 
trials raises ethical issues.[2] It is always advisable to take 
the help of a statistician both during the analysis of data 
and design of clinical trials.[3] Not associating a statistician 
while designing clinical trials is associated with the poor 
reporting of statistical parameters in clinical trials.[3]
This study is designed to check the function of statisticians 
in clinical trials published in five Indian medical journals and 
see the impact of employing these statisticians on reporting 
of some important statistical parameters. Clinical trials 
published in four Indian medical journals were selected 
for analysis. Statistical parameters selected for comparisons 
were the following: calculation of sample size, sample size, 
calculation of power, appropriate statistical tests, significant 
P value after Bonferroni correction, number of primary 
endpoints, and calculation of post hoc power of the study. 
All clinical trials published in four Indian medical 
journals in 9 years (January 2000 to December 2008) were 
downloaded. Each author critically appraised these clinical 
trials for the various statistical parameters on the basis of a 
predesigned proforma. Information regarding the role of a 
statistician was seen at authors’ section, acknowledgement, 
and methods section of clinical trials. These trials were 
also appraised for information on calculation of sample 
size, even partial calculation of sample size were taken into 
account. Information regarding the exact sample size was 
noted in the proforma. Authors also surveyed all clinical 
trials for information regarding calculation of power before 
starting of study (design phase). Appropriate statistical 
tests were evaluated based on the aim of the study, type 
of data, and distribution of data. These clinical trials were 
also appraised for methods of adjustment of multiple 
endpoints and whether the P value is still significant 
after adjustment of multiple endpoints on the basis of 
Bonferroni correction. Endpoints are considered as events 
or outcomes that can be measured objectively to determine 
whether the intervention being studied is beneficial. We 
did not include adverse effects as endpoints of trials. Post 
hoc power of trials was also calculated at 50% difference 
between the outcomes with the help of G Power software.[4] 
Discrepancies observed between the authors were resolved 
by consensus. 
Qualitative data (sample size calculation, power calculation, 
appropriate statistical tests, significant P value after 
Bonferroni correction and post hoc power calculation 
(>80%) for the 50% difference in the outcome) were 
expressed in frequency and percentage. Difference between 
the group was analyzed by Chi-square test (with Yates 
correction where appropriate). Quantitative data (sample 
size, number of primary endpoints) were expressed as 
mean and difference between the groups analyzed by 
using unpaired t test. Before using unpaired t test, normal 
distribution of data was confirmed by Skewness, Kurtosis, 
Kolmogorov Smirnov test, and Shapiro Wilk test. SPSS for 
Window ver. 17 was used for analysis. Post hoc power was 
calculated by G Power software. 
A total of 68 clinical trials were collected, of which the 
role of a statistician was acknowledged in 13 trials (19.1%, 
95% CI: 11.5%-30%). Of the 13 clinical trials in which the 
help of a statistician was acknowledged, 8 (61.5%) were 
positive and in the remaining 55 trials, 27 (49%) were 
positive. There was statistically significant difference in the 
number of primary endpoints and sample size between the 
two groups. Other statistical parameters were not different 
statistically [Table 1]. Therefore, based on this study, we can 
conclude that a statistician does not seems to contribute 168   Journal of Young Pharmacists Vol 3 / No 2
much in correct reporting of statistical parameters, except 
sample size and number of primary endpoints. 
This study has some limitations, one of which is its small 
sample size (Indian medical journals and clinical trials) for 
analysis. Another limitation here was difficulty in knowing 
the time of intervention by statisticians, whether he/she 
has contributed from the start of the clinical trial (design 
phase) or only during analysis of results. Another limitation 
may be under-reporting of the role of statistician. In this 
study, Bonferroni correction was used for adjustment of 
multiple endpoints. This method of adjustment becomes 
less reliable, as the number of endpoints increase.  
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Pharmacovigilance: A 
Worldwide Master Key for 
Drug Safety Monitoring: Some 
Additional Information
Sir,
I have read the article titled “Pharmacovigilance: A 
worldwide master key for drug safety monitoring,” and 
I found the topic quite informative and it also included 
recent updates. So first of all, I congratulate the authors 
for such a nice compilation. It covers almost all areas; 
however, I would like to add more information about 
pharmacovigilance in vaccines. The great challenge here 
is to convey a proper message to the general public as 
it is like a double-edged sword.[1] Majority of vaccines 
are administered to vulnerable (children) as well as 
healthy population that requires strict safety supervision. 
Therefore, the safety of a vaccination must be more than 
other pharmacological agents to make it acceptable in 
general population.[2]
According to WHO, the adverse event following 
immunization (AEFI) is “a medical incident that takes place 
after an immunization causes concern, and is believed to be 
caused by the immunization.” Vaccines are biological agents 
given prophylactically to protect target population again 
specific infection by immunological action.[2] Following 
points favor different pharmacovigilance for vaccines and 
drugs:
1.  Complex vaccine sources
  Vaccines are complex biological products, which may 
include multiple antigens, live organisms, adjuvants, 
and preservatives. Adverse drug reactions (ADRs) may 
be due to the administration of live wild viruses, e.g., 
lymphocyte meningitis after anti-mumps vaccine or 
may be non-specific, related to a component different 
from the antigen (aluminum hydroxide involved in 
Table 1: Difference between various statistical parameters between both groups
Frequencies→
Groups ↓ 
Sample size 
calculated
Sample size 
(Mean (SD))
Calculation of 
Power
Appropriate 
statistical tests
Significant P value 
after Bonferroni 
correction
Post hoc >80% 
power for large 
difference
Number of 
Primary endpoints   
(Mean (SD))
Statistician (n=13) 7 (53.8) 58.8 (24.2) 7 (53.8) 12 (92.3) 9 (69.2) 11 (84.6) 1.42 (0.51)
Non Statistician (n=55) 22 (40) 41.8 (23.3) 20 (36.3) 50 (90.9) 30 (54.5) 41 (74.5) 2.16 (0.89)
P value 0.36 0.019 0.24 0.87 0.33 0.48 0.005
Statistical test Chi-square test Unpaired t test Chi-square test Chi-square test 
(Yates correction)
Chi-square test 
(Yates correction)
Chi-square test 
(Yates correction)
Unpaired t test
Values in parentheses are percentages
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